ReNetX Bio reports that the FDA has granted the company Fast Track Designation for ReNetX Bio’s clinical therapy (AXER-204) for the potential treatment of Chronic Spinal Cord Injury (SCI).
ReNetX Bio is currently conducting a Phase 1/2 clinical trial “RESET” in patients with SCI, with topline results expected in 2021.
SCI is a serious and currently incurable medical condition which causes profound deficits in function and impairs the ability to carry out activities of daily living (ADLs) and affects roughly 300,000 people in the United States. more